Hepatocellular Carcinoma (HCC) Clinical Trial
Official title:
Efficacy and Safety of Lenvatinib as a Conversion Therapy in Patients With Potentially Resectable Hepatocellular Carcinoma: A Single-Arm and Open-Label Prospective Study
Lenvatinib is the standard of care for patients with advanced hepatocellular carcinoma (HCC). The aim of the single-arm, open-label, phase II clinical trial is to assess efficacy and safety of lenvatinib as a preoperative conversion therapy in patients with potentially resectable HCC. Investigator hypothesized that lenvatinib may be an effective conversion treatment for HCC, and preoperative treatment with lenvatinib can improve resectability in patients with potential resectable HCC and improve the long term survival.
For patients with potentially resectable HCC (intermediate or advanced stage), upfront
therapy with surgical resection is of high recurrence rate after surgery. The aim of the
single-arm, open-label, prospective phase II clinical trial is to evaluate whether
preoperative lenvatinib treatment could improve resectability and therefore improve the long
term survival.
Participants who are recruited in this study in this study will be treated with lenvatinib
and will be evaluated for the feasibility for surgical resection by a multidisciplinary team
every 8 weeks. If the participants underwent curative resection, they will receive lenvatinib
treatment for 48 weeks after surgery.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03007212 -
Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis
|
Phase 4 | |
| Terminated |
NCT03236649 -
The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
|
Phase 3 | |
| Withdrawn |
NCT04044326 -
The Safety and Efficacy of Spherical Microwave Ablation for the Treatment of Malignant Liver Tumors
|
N/A | |
| Recruiting |
NCT04687969 -
Multimodal Machine Learning Characterization of Solid Tumors
|
||
| Completed |
NCT02562755 -
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
|
Phase 3 | |
| Withdrawn |
NCT02406508 -
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
|
Phase 2 | |
| Completed |
NCT01972672 -
The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT01247298 -
A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma
|
Phase 0 | |
| Completed |
NCT03735628 -
An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT02188901 -
Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study
|
N/A | |
| Active, not recruiting |
NCT04522908 -
Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function
|
Phase 2 | |
| Terminated |
NCT01433016 -
Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI
|
Phase 2 | |
| Withdrawn |
NCT04465734 -
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
|
Phase 3 | |
| Recruiting |
NCT05057013 -
HMBD-001 in Advanced HER3 Positive Solid Tumours
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03753659 -
IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)
|
Phase 2 | |
| Terminated |
NCT03144661 -
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT01821482 -
A Study of DC-CIK to Treat Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT03516071 -
A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
|
Phase 2 | |
| Completed |
NCT01761266 -
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
|
Phase 3 | |
| Not yet recruiting |
NCT06345001 -
A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer
|
Phase 1 |